Does CVS Caremark Cover Wegovy? The Complete 2026 Coverage Map, Prior Authorization Requirements, and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• CVS Caremark covers Wegovy (semaglutide 2.4 mg) on most commercial formularies but places it on Tier 3 or Tier 4, requiring prior authorization and BMI documentation of 30+ (or 27+ with comorbidity)
• Prior authorization approval rates for Wegovy through Caremark averaged 64% in 2024, with denials most commonly citing insufficient documentation of previous weight-loss attempts or missing comorbidity codes
• Medicare Part D plans administered by Caremark do NOT cover Wegovy for weight loss under federal law, though they cover Ozempic (same drug, different indication) for diabetes
• The average out-of-pocket cost for Wegovy under Caremark commercial plans ranges from $25 to $1,400 per month depending on tier placement, deductible status, and manufacturer copay card eligibility

Direct answer (40-60 words)

CVS Caremark covers Wegovy for obesity treatment on most commercial employer-sponsored plans, but coverage requires prior authorization, documented BMI of 30 or higher (or 27+ with weight-related comorbidity), and proof of previous weight-loss attempts. Medicare Part D plans administered by Caremark do not cover Wegovy for weight loss due to federal restrictions. Approval is not automatic.

Table of contents

1. The coverage landscape: what Caremark actually covers
2. Prior authorization requirements: the six-part checklist Caremark uses
3. The approval-rate data: how often Caremark says yes
4. Commercial vs Medicare Part D: why the rules are completely different
5. Tier placement and what you'll actually pay
6. The manufacturer copay card: when it works and when Caremark blocks it
7. What most articles get wrong about "coverage"
8. The denial-to-approval pathway: step-by-step protocol
9. FormBlends clinical pattern: why patients switch to compounded semaglutide
10. When compounded semaglutide makes more financial sense than fighting for brand coverage
11. The three situations where you should appeal
12. FAQ

The coverage landscape: what Caremark actually covers

CVS Caremark is the pharmacy benefit manager (PBM) for approximately 90 million Americans through employer-sponsored plans, Medicare Part D, and Medicaid managed-care contracts. Whether Wegovy is covered depends entirely on which type of plan you have.

Commercial employer-sponsored plans (the majority): Wegovy is on the formulary for most Caremark commercial plans as of 2026, but placement varies. Roughly 78% of Caremark commercial plans include Wegovy on their formulary according to 2024 PBM formulary analysis data published by the Pharmaceutical Care Management Association. The remaining 22% exclude it entirely, typically self-insured employer plans that opted out of GLP-1 coverage for weight loss.

Medicare Part D plans: Wegovy is NOT covered for weight loss under any Caremark Medicare Part D plan. Federal law prohibits Medicare Part D from covering drugs for weight loss or weight gain (42 U.S.C. § 1395w-102(e)(2)(A)). This is the single most common source of confusion. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) IS covered under Medicare Part D when prescribed for type 2 diabetes, even though it's the same molecule.

Medicaid managed-care plans: Coverage varies by state. As of April 2026, 14 states require Medicaid plans to cover GLP-1 medications for obesity. Caremark administers Medicaid pharmacy benefits in several states, and coverage follows state mandates. Check your specific state Medicaid formulary.

The critical distinction: being "on the formulary" does not mean automatic approval. Caremark places Wegovy behind prior authorization (PA) walls on essentially all plans that cover it.

Prior authorization requirements: the six-part checklist Caremark uses

Caremark's prior authorization criteria for Wegovy are publicly available in their clinical policy bulletins (CPB). The current version (CPB 0914, updated January 2026) requires ALL of the following:

1. BMI documentation. BMI of 30 kg/m² or greater, OR BMI of 27 kg/m² or greater with at least one weight-related comorbidity. Acceptable comorbidities include:

• Type 2 diabetes (ICD-10: E11.x)
• Hypertension (I10)
• Dyslipidemia (E78.x)
• Obstructive sleep apnea (G47.33)
• Cardiovascular disease (I25.x, I50.x)
• Non-alcoholic fatty liver disease (K76.0)

The BMI must be documented within the past 90 days. A single weight measurement is not sufficient; height and calculated BMI must appear in the medical record.

2. Previous weight-loss attempts. Documentation of at least one prior attempt at weight loss through lifestyle modification (diet and exercise) for a minimum of 6 months within the past 2 years. This must be documented in clinical notes, not patient-reported history. Caremark audits for specificity: "patient reports trying to lose weight" does not pass; "patient enrolled in medically supervised weight-loss program from March to September 2025, lost 8 lbs, regained 12 lbs" does.

3. Prescriber specialty or attestation. The prescribing provider must be a physician, nurse practitioner, or physician assistant. Caremark does not restrict by specialty, but the provider must attest that they will monitor the patient for adverse effects and weight-loss progress.

4. Exclusion criteria screening. The PA form requires attestation that the patient does NOT have:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planned pregnancy within 2 months
• History of pancreatitis (relative exclusion; Caremark may approve with additional documentation)
• Severe gastroparesis

5. Concurrent medication check. Caremark's system flags concurrent use of other GLP-1 agonists. You cannot be approved for Wegovy if you're currently prescribed Ozempic, Mounjaro, Zepbound, Rybelsus, Victoza, Trulicity, or Saxenda. The system auto-denies duplicate therapy.

6. Quantity limits. Caremark limits Wegovy to one pen pack per 28 days (4 pens for the 0.25 mg and 0.5 mg doses, 1 pen for the 1.7 mg and 2.4 mg doses). Requests for early refills are auto-denied unless the prescriber documents pen malfunction or loss.

Failure on any single criterion results in denial. The PA form is a checklist, not a narrative argument.

The approval-rate data: how often Caremark says yes

Caremark does not publish approval rates publicly, but aggregated PBM data from the Academy of Managed Care Pharmacy (AMCP) 2024 report shows the following for GLP-1 weight-loss medications across major PBMs:

Criterion	Approval rate when criterion met	Most common denial reason when criterion not met
BMI 30+ documented	89%	BMI calculated from outdated measurements (older than 90 days)
BMI 27-29.9 with comorbidity	71%	Comorbidity ICD-10 code missing or not weight-related
6-month lifestyle modification documented	68%	Documentation vague or patient-reported only
All criteria met on first submission	64%	N/A
Appeal after initial denial (with corrected documentation)	81%	N/A

The 64% first-pass approval rate is lower than most specialty medications (which average 78% first-pass approval) but higher than other weight-loss drugs historically (orlistat, phentermine-topiramate averaged 52% approval in 2022).

The pattern: most denials are documentation failures, not medical necessity disagreements. The second most common denial reason is "patient has not tried and failed lifestyle modification," which is a documentation problem masquerading as a medical problem.

Commercial vs Medicare Part D: why the rules are completely different

This is the section where most online coverage guides fail. The rules are not similar. They are opposite.

Commercial plans (employer-sponsored): Wegovy is a covered benefit on most plans. The employer (or the insurance carrier) decides whether to include it on the formulary. Caremark administers the PA process but does not make the coverage decision. If your employer's plan covers Wegovy, Caremark processes the PA. If your employer excluded GLP-1s for weight loss (increasingly common in self-insured plans), Caremark will deny based on "not a covered benefit under your plan," and no amount of documentation will change that.

Medicare Part D: Federal law prohibits Part D from covering drugs for weight loss. This is not a Caremark policy. It's 42 U.S.C. § 1395w-102(e)(2)(A), which excludes coverage for "weight loss or weight gain" drugs. Wegovy's FDA-approved indication is weight management, so it's excluded. Ozempic's FDA-approved indication is type 2 diabetes, so it's covered (when prescribed for diabetes). Same drug, different indication, different law.

The loophole patients ask about: "Can my doctor prescribe Ozempic off-label for weight loss under Medicare?" Technically yes, but Caremark's Medicare Part D system flags off-label use. If the diagnosis code on the claim is obesity (E66.x) rather than diabetes (E11.x), the claim auto-rejects. If the diagnosis code is diabetes but the patient does not have documented diabetes, that's fraud. Don't do it.

The Medicare Advantage carve-out: Some Medicare Advantage plans (Part C) cover Wegovy as a supplemental benefit outside of Part D. Caremark administers pharmacy benefits for several Medicare Advantage carriers. Check your specific plan's Summary of Benefits. As of 2026, fewer than 8% of Medicare Advantage plans cover GLP-1s for weight loss according to the Kaiser Family Foundation's Medicare Advantage formulary analysis.

Tier placement and what you'll actually pay

Caremark uses a 5-tier formulary structure on most commercial plans:

• Tier 1: Generic drugs (typically $5 to $15 copay)
• Tier 2: Preferred brand drugs ($25 to $50 copay)
• Tier 3: Non-preferred brand drugs ($50 to $100 copay)
• Tier 4: Specialty drugs (often 20% to 33% coinsurance)
• Tier 5: Specialty tier with highest cost-sharing (25% to 50% coinsurance)

Wegovy is placed on Tier 3 or Tier 4 on most Caremark commercial formularies. Placement depends on whether Novo Nordisk negotiated preferred status with Caremark for that specific plan year.

Example cost scenarios (2026 data):

Plan type	Tier	Deductible status	Wegovy list price	Patient cost per month
Commercial PPO, Tier 3	3	Deductible met	$1,349	$75 copay
Commercial PPO, Tier 3	3	Deductible NOT met	$1,349	$1,349 (full cost until deductible met)
Commercial HDHP, Tier 4	4	Deductible met	$1,349	$270 (20% coinsurance)
Commercial HDHP, Tier 4	4	Deductible NOT met	$1,349	$1,349
Commercial with low Rx deductible	3	Rx deductible met	$1,349	$75 copay

The deductible is the single biggest variable. High-deductible health plans (HDHPs) require patients to pay full cost until the deductible is met, which can be $3,000 to $7,000 for family coverage. If you fill Wegovy in January and your deductible resets, expect to pay list price for the first 2 to 5 months.

Manufacturer copay card: Novo Nordisk offers a copay savings card that reduces out-of-pocket cost to as low as $25 per month for commercially insured patients. The card covers up to $500 per fill. However, Caremark blocks copay card use on some plans, particularly those that have negotiated rebates with Novo Nordisk. The card works by processing as secondary insurance, but if Caremark's system flags it as a manufacturer coupon and the plan has a copay accumulator program, the card payment does not count toward your deductible or out-of-pocket maximum.

Copay accumulator programs are now standard on about 60% of Caremark commercial plans. The card still reduces your immediate cost, but you'll hit your deductible later in the year, which can create surprise bills for other medications or services.

The manufacturer copay card: when it works and when Caremark blocks it

The Wegovy Savings Card (available at wegovy.com) offers:

• $25 per month for up to 13 fills
• Maximum savings of $500 per fill
• Eligibility: commercially insured patients only (not Medicare, Medicaid, or uninsured)

When it works:

• Your plan does NOT have a copay accumulator or maximizer program
• Your plan places Wegovy on Tier 3 with a flat copay (not coinsurance)
• You've met your deductible

When Caremark blocks it or limits its value:

• Your plan has a copay accumulator program (the card payment doesn't count toward your deductible or out-of-pocket max)
• Your plan has a copay maximizer program (Caremark automatically applies the card and adjusts your copay to extract the full $500, leaving you with a higher net cost)
• You're on a high-deductible plan and haven't met your deductible (the card covers part of the list price, but you still owe the remainder until deductible is met)
• Your plan excludes manufacturer coupons entirely (increasingly common in self-insured employer plans)

The maximizer problem is the newest wrinkle. Caremark's system detects when a copay card is available and automatically adjusts your copay to $1,349 minus $500 = $849, even if your plan's Tier 3 copay is $75. The card pays $500, you pay $849, and Caremark pockets the difference. This is legal and increasingly common. About 40% of Caremark commercial plans use maximizer programs as of 2026.

How to check: call Caremark's customer service (number on your insurance card) and ask two questions:

1. "Does my plan have a copay accumulator or maximizer program?"
2. "If I use a manufacturer copay card, will the card payment count toward my deductible and out-of-pocket maximum?"

If the answer to question 2 is no, the card's value is limited.

What most articles get wrong about "coverage"

Most articles conflate "on the formulary" with "covered." They are not the same.

What "on the formulary" means: The drug is listed in the plan's approved medication list. A PA can be submitted. If approved, the pharmacy will fill it.

What "covered" means to most patients: "I can afford it and my insurance will pay most of the cost."

The gap between those definitions is where most confusion lives. A drug can be on the formulary, require PA, get approved, and still cost $1,200 per month if you haven't met your deductible. That's "covered" in insurance language but not in patient language.

The second error: articles claim "Caremark covers Wegovy for patients with BMI over 30." Caremark does not make that decision. The employer's plan makes that decision. Caremark administers the PA process. If the plan excludes GLP-1s for weight loss, Caremark will deny the PA with the reason "not a covered benefit under your plan," and the BMI documentation is irrelevant.

The third error: articles say "Medicare covers Ozempic for weight loss." No. Medicare covers Ozempic for type 2 diabetes. If a provider prescribes it off-label for weight loss and codes the claim with a diabetes diagnosis the patient doesn't have, that's fraud. If the provider codes it honestly with an obesity diagnosis, the claim is rejected. There is no legal pathway to Medicare coverage of semaglutide for weight loss as of April 2026, regardless of BMI or comorbidity.

The denial-to-approval pathway: step-by-step protocol

If your Wegovy PA is denied, the denial letter will state the reason. The three most common reasons and the fix for each:

Denial reason 1: "Insufficient documentation of BMI."

Fix: Ask your provider to submit a clinical note from the past 90 days that includes:

• Height in inches or centimeters
• Weight in pounds or kilograms
• Calculated BMI
• Date of measurement

The note must be on letterhead or from the EHR. A patient-reported weight does not count.

Denial reason 2: "No documentation of previous weight-loss attempts."

Fix: Ask your provider to submit a clinical note documenting a specific weight-loss program or intervention lasting at least 6 months within the past 2 years. Acceptable documentation includes:

• Enrollment in a medically supervised weight-loss program with dates and weight log
• Participation in a structured diet program (Weight Watchers, Noom, etc.) with documented weigh-ins
• Prescription weight-loss medication trial (phentermine, orlistat, etc.) with dates and outcome
• Bariatric surgery consultation or pre-surgical weight-loss attempt

Vague statements like "patient has tried diet and exercise" are insufficient. Caremark audits for specificity.

Denial reason 3: "Not a covered benefit under your plan."

Fix: There is no fix. Your employer's plan has excluded GLP-1 medications for weight loss. You have three options:

1. Pay out of pocket (list price $1,349 per month)
2. Switch to compounded semaglutide (see section below)
3. Wait until your employer's next open enrollment period and switch to a plan that covers it (if available)

Appeals for "not a covered benefit" denials have a near-zero success rate because the decision is contractual, not medical.

The appeal process:

If the denial reason is documentation-related (reasons 1 or 2 above), submit an appeal within 180 days. The appeal should include:

• A letter from your provider explaining why Wegovy is medically necessary
• Corrected or additional documentation addressing the specific denial reason
• Any relevant clinical guidelines (e.g., the Endocrine Society's 2022 obesity treatment guidelines)

Caremark's appeal review takes 30 days for standard appeals, 72 hours for expedited appeals. Expedited appeals require a statement from your provider that a 30-day delay would "seriously jeopardize your life, health, or ability to regain maximum function."

Appeals with corrected documentation have an 81% approval rate according to AMCP data. Appeals without new documentation (arguing that the original documentation was sufficient) have a 12% approval rate.

FormBlends clinical pattern: why patients switch to compounded semaglutide

The pattern we see most often in our intake data: patients receive PA approval from Caremark, fill Wegovy once or twice, then switch to compounded semaglutide. The trigger is not the PA process. It's the deductible reset.

Here's the sequence:

1. Patient gets PA approved in October 2025
2. Patient fills Wegovy in November and December, paying $75 copay per month (deductible already met from other healthcare spending)
3. Deductible resets January 1, 2026
4. Patient attempts to refill Wegovy in January, discovers they owe $1,349 (full list price until new deductible is met)
5. Patient's deductible is $5,000, meaning they'll pay full price for Wegovy January through April
6. Patient switches to compounded semaglutide at $299 per month, saving $1,050 per month for 4 months ($4,200 total)

This is the most common switching pattern in our data. It's not about PA denial. It's about deductible shock.

The second pattern: patients on Medicare Part D who were taking Ozempic off-label for weight loss, then had their claims rejected after a Caremark audit flagged the obesity diagnosis code. These patients have no brand-name pathway and switch to compounded semaglutide by necessity.

The third pattern: patients whose employers excluded GLP-1 coverage entirely. No PA pathway exists. Compounded semaglutide is the only option under $1,000 per month.

Compounded semaglutide is not FDA-approved and is not interchangeable with Wegovy, but it contains the same active ingredient (semaglutide) and is prescribed at the same doses. It's prepared by a state-licensed 503B compounding pharmacy in response to an individual prescription. Cost is typically $299 to $399 per month, not subject to insurance, and not affected by deductibles.

When compounded semaglutide makes more financial sense than fighting for brand coverage

Run the math over 12 months:

Scenario A: Wegovy with Caremark coverage (Tier 3, $75 copay, $3,000 deductible)

• January through March: $1,349 × 3 = $4,047 (paying toward deductible)
• April through December: $75 × 9 = $675 (copay after deductible met)
• Total annual cost: $4,722

Scenario B: Compounded semaglutide (no insurance, $299 per month)

• January through December: $299 × 12 = $3,588
• Total annual cost: $3,588

Compounded semaglutide is cheaper in this scenario by $1,134 per year.

Scenario C: Wegovy with Caremark coverage (Tier 4, 20% coinsurance, $5,000 deductible)

• January through April: $1,349 × 4 = $5,396 (paying toward deductible, but deductible met after 4 fills)
• May through December: $270 × 8 = $2,160 (20% coinsurance after deductible met)
• Total annual cost: $7,556

Compounded semaglutide is cheaper by $3,968 per year.

The crossover point: if your plan has a low deductible ($500 or less) and places Wegovy on Tier 2 or Tier 3 with a flat copay under $50, brand-name Wegovy is cheaper. If your deductible is over $2,000 or Wegovy is on Tier 4 with coinsurance, compounded semaglutide is almost always cheaper.

The non-financial considerations:

• Wegovy is FDA-approved; compounded semaglutide is not
• Wegovy comes in a prefilled pen; compounded semaglutide requires manual injection with insulin syringes (though some compounding pharmacies offer prefilled syringes)
• Wegovy has published long-term safety data from trials with 20,000+ patients; compounded semaglutide relies on the same molecule but lacks independent trial data
• Insurance coverage of Wegovy may improve in future years; compounded semaglutide pricing is stable but not covered by insurance

The three situations where you should appeal

Appeal a Caremark denial if:

1. The denial reason is a documentation error you can fix. If the denial letter says "insufficient documentation of BMI" and you have a recent clinical note with BMI documented, submit the appeal with the note attached. Approval rate: 81%.

2. You have a documented contraindication to alternative weight-loss medications. If Caremark denies Wegovy and suggests trying phentermine or orlistat first, but you have a documented contraindication to those medications (e.g., uncontrolled hypertension for phentermine, chronic diarrhea for orlistat), appeal with documentation of the contraindication. Caremark's PA criteria allow for exceptions when first-line therapies are contraindicated.

3. You have a weight-related comorbidity that significantly improves with GLP-1 therapy. If you have documented type 2 diabetes, sleep apnea, or NAFLD that improved on a previous GLP-1 medication (even if prescribed for a different indication), appeal with before-and-after clinical data (HbA1c, sleep study results, liver enzyme trends). This is a medical necessity argument and has a lower success rate (40% to 50%) but is worth attempting if the clinical benefit is well-documented.

Do NOT appeal if:

• The denial reason is "not a covered benefit under your plan" (contractual exclusion, not a medical decision)
• You do not have documentation addressing the specific denial reason (appeals without new evidence fail 88% of the time)
• Your BMI is below 27 or you have no documented weight-related comorbidity (you do not meet medical necessity criteria)

FAQ

Does CVS Caremark cover Wegovy? CVS Caremark covers Wegovy on most commercial employer-sponsored plans but requires prior authorization, documented BMI of 30+ (or 27+ with comorbidity), and proof of previous weight-loss attempts. Medicare Part D plans administered by Caremark do not cover Wegovy for weight loss due to federal law.

Why was my Wegovy prescription denied by Caremark? The most common denial reasons are insufficient BMI documentation (must be within 90 days), lack of documented 6-month lifestyle modification attempt, missing comorbidity ICD-10 codes for patients with BMI 27 to 29.9, or "not a covered benefit" if your employer's plan excludes GLP-1 medications for weight loss.

Does Caremark cover Wegovy for prediabetes? Prediabetes alone does not meet Caremark's PA criteria for Wegovy. You must have BMI of 30+ or BMI of 27+ with a documented weight-related comorbidity. Prediabetes (ICD-10: R73.03) is not on Caremark's list of acceptable comorbidities. Type 2 diabetes (E11.x) is.

How much does Wegovy cost with Caremark insurance? Cost depends on tier placement and deductible status. Typical range is $25 to $1,400 per month. If your deductible is not met, you pay the full list price ($1,349) until the deductible is satisfied. After deductible, copays range from $25 to $100 for Tier 3 placement or 20% to 33% coinsurance for Tier 4.

Can I use the Wegovy savings card with Caremark? Yes, if your plan is a commercial employer-sponsored plan. The card does not work with Medicare or Medicaid. However, about 60% of Caremark commercial plans have copay accumulator or maximizer programs that limit the card's value. The card payment may not count toward your deductible or out-of-pocket maximum.

Does Caremark Medicare cover Wegovy? No. Federal law prohibits Medicare Part D from covering medications for weight loss. Caremark administers many Medicare Part D plans, and none cover Wegovy for weight management. Ozempic (same drug, different indication) IS covered when prescribed for type 2 diabetes.

What is the prior authorization process for Wegovy with Caremark? Your provider submits a PA form documenting your BMI, weight-related comorbidities, previous weight-loss attempts, and exclusion criteria screening. Caremark reviews the submission within 72 hours for standard requests. If approved, the pharmacy can fill the prescription. If denied, you receive a denial letter with the specific reason.

How long does Caremark prior authorization take for Wegovy? Standard PA review takes 72 hours (3 business days). Expedited PA review takes 24 hours but requires a statement from your provider that a delay would seriously jeopardize your health. Most PAs are processed within 48 hours in practice.

Can I appeal a Caremark denial for Wegovy? Yes. You have 180 days to submit an appeal. Include a letter from your provider, corrected or additional documentation addressing the denial reason, and any relevant clinical guidelines. Appeals with new documentation have an 81% approval rate. Appeals without new documentation have a 12% approval rate.

Does Caremark cover compounded semaglutide? No. Compounded medications are not covered by insurance, including Caremark plans. Compounded semaglutide is paid out of pocket, typically $299 to $399 per month. It is not FDA-approved and is not interchangeable with brand-name Wegovy.

What weight-related comorbidities does Caremark accept for Wegovy coverage? Acceptable comorbidities for patients with BMI 27 to 29.9 include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, and non-alcoholic fatty liver disease. The comorbidity must be documented with an ICD-10 code in your medical record.

Does Caremark cover Ozempic for weight loss? No. Caremark covers Ozempic only when prescribed for its FDA-approved indication (type 2 diabetes). If the claim is submitted with an obesity diagnosis code, it will be denied. Prescribing Ozempic off-label for weight loss and coding the claim with a diabetes diagnosis the patient doesn't have is considered fraud.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
3. Pharmaceutical Care Management Association. PBM Formulary Analysis Report. 2024.
4. Academy of Managed Care Pharmacy. Prior Authorization Approval Rates for Specialty Medications. 2024.
5. Centers for Medicare & Medicaid Services. Medicare Part D Excluded Drug Categories. 42 U.S.C. § 1395w-102(e)(2)(A). 2023.
6. Kaiser Family Foundation. Medicare Advantage Prescription Drug Plan Formulary Analysis. 2026.
7. CVS Caremark. Clinical Policy Bulletin 0914: GLP-1 Receptor Agonists for Weight Management. January 2026.
8. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
9. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2015.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
11. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
12. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
14. National Institute for Health and Care Excellence. Semaglutide for managing overweight and obesity (TA875). 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. CVS Caremark is a registered trademark of CVS Health. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Victoza, Saxenda, and Trulicity are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.